Biallelic DICER1 mutations occur in Wilms tumours

Journal of Pathology

Volumn 230, Issue 2, 2013, Pages 154-164

  Wu, M K ^a   Sabbaghian, N ^a   Xu, B ^b   Addidou Kalucki, S ^a   Bernard, C ^b   Zou, D ^c   Reeve, A E ^c   Eccles, M R ^d   Cole, C ^e   Choong, C S ^e,f   Charles, A ^e,f   Tan, T Y ^g   Iglesias, D M ^h   Goodyer, P R ^h   Foulkes, W D ^a,h,i  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^g ROYAL CHILDREN'S HOSPITAL   (Australia)

^h RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

Author keywords

exon splicing silencer; miRNA; paediatric tumours

Indexed keywords

DICER; DICER 1; MICRORNA; RIBONUCLEASE III; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL FEATURE; EXON SKIPPING; FEMALE; GENE DELETION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HYPOTHESIS; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN DOMAIN; SOMATIC MUTATION;

ANIMALS; CERCOPITHECUS AETHIOPS; CHILD, PRESCHOOL; COS CELLS; DEAD-BOX RNA HELICASES; EXONS; FEMALE; GERM-LINE MUTATION; HUMANS; KIDNEY NEOPLASMS; MALE; MUTATION, MISSENSE; RIBONUCLEASE III; WILMS TUMOR;

EID: 84877731972     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4196     Document Type: Article

References (59)

1. Huff V., Wilms' tumor genetics. Am J Med Genet 1998; 79: 260-267.
2. Rivera MN, Haber DA,. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005; 5: 699-712.
3. Van Heyningen V, Hastie ND,. Wilms' tumour: reconciling genetics and biology. Trends Genet 1992; 8: 16-21.
4. Sharpe CR, Franco EL,. Etiology of Wilms' tumor. Epidemiol Rev 1995; 17: 415-432.
5. Md Zin R, Murch A, Charles A,. Pathology, genetics and cytogenetics of Wilms' tumour. Pathology 2011; 43: 302-312.
6. Astuti D, Morris MR, Cooper WN, et al. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms' tumor susceptibility. Nat Genet 2012; 44: 277-284.
7. Slade I, Bacchelli C, Davies H, et al. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 2011; 48: 273-278.
8. Foulkes WD, Bahubeshi A, Hamel N, et al. Extending the phenotypes associated with DICER1 mutations. Hum Mutat 2011; 32: 1381-1384.
9. Williams RD, Al-Saadi R, Chagtai T, et al. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res 2010; 16: 2036-2045.
10. Scott RH, Murray A, Baskcomb L, et al. Stratification of Wilms' tumor by genetic and epigenetic analysis. Oncotarget 2012; 3: 327-335.
11. Cowell JK, Groves N, Baird P,. Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene. Br J Cancer 1993; 67: 1259-1261.
12. Strong LC,. The two-hit model for Wilms' tumor: where are we 30 years later? Genes Chromosomes Cancer 2003; 38: 294-299.
13. Wadey RB, Pal N, Buckle B, et al. Loss of heterozygosity in Wilms' tumour involves two distinct regions of chromosome 11. Oncogene 1990; 5: 901-907.
14. Gadd S, Huff V, Huang CC, et al. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms' tumor: a Children's Oncology Group Study. Neoplasia 2012; 14: 742-756.
15. Huang A, Campbell CE, Bonetta L, et al. Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms' tumor. Science 1990; 250: 991-994.
16. Guertl B, Leuschner I, Harms D, et al. Genetic clonality is a feature unifying nephroblastomas regardless of the variety of morphological subtypes. Virchows Arch 2006; 449: 171-174.
17. Knudson AG Jr, Strong LC,. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972; 48: 313-324.
18. Solomon E., Recessive mutation in aetiology of Wilms' tumour. Nature 1984; 309: 111-112.
19. Orkin SH, Goldman DS, Sallan SE,. Development of homozygosity for chromosome 11p markers in Wilms' tumour. Nature 1984; 309: 172-174.
20. Reeve AE, Housiaux PJ, Gardner RJ, et al. Loss of a Harvey ras allele in sporadic Wilms' tumour. Nature 1984; 309: 174-176.
21. Fearon ER, Vogelstein B, Feinberg AP,. Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumours. Nature 1984; 309: 176-178.
22. Eccles MR, Millow LJ, Wilkins RJ, et al. Harvey-ras allele deletion detected by in situ hybridization to Wilms' tumor chromosomes. Hum Genet 1984; 67: 190-192.
23. Chakravarthy S, Sternberg SH, Kellenberger CA, et al. Substrate-specific kinetics of Dicer-catalyzed RNA processing. J Mol Biol 2010; 404: 392-402.
24. Carthew RW,. Gene regulation by microRNAs. Curr Opin Genet Dev 2006; 16: 203-208.
25. Tang KF, Song GB, Shi YS, et al. Dicer knockdown induces fibronectin-1 expression in HEK293T cells via induction of Egr1. Biochim Biophys Acta 2010; 1800: 380-384.
26. Tang KF, Wang Y, Wang P, et al. Upregulation of PHLDA2 in Dicer knockdown HEK293 cells. Biochim Biophys Acta 2007; 1770: 820-825.
27. Bahubeshi A, Bal N, Rio Frio T, et al. Germline DICER1 mutations and familial cystic nephroma. J Med Genet 2010; 47: 863-866.
28. Wildi-Runge S, Bahubeshi A, Carret AS, et al. New phenotype in the familial DICER1 tumor syndrome: pituitary blastoma presenting at age 9 months. Endocr Rev 2011; 32: P1-777.
29. Schultz KA, Pacheco MC, Yang J, et al. Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol 2011; 122: 246-250.
30. Carmell MA, Hannon GJ,. RNase III enzymes and the initiation of gene silencing. Nat Struct Mol Biol 2004; 11: 214-218.
31. Lau PW, Guiley KZ, De N, et al. The molecular architecture of human Dicer. Nat Struct Mol Biol 2012; 19: 436-440.
32. Merritt WM, Bar-Eli M, Sood AK,. The dicey role of Dicer: implications for RNAi therapy. Cancer Res 2010; 70: 2571-2574.
33. Ohishi K, Nakano T,. A forward genetic screen to study mammalian RNA interference-essential role of RNase IIIa domain of Dicer1 in 3′ strand cleavage of dsRNA in vivo. FEBS J 2012; 279: 832-843.
34. Takeshita D, Zenno S, Lee WC, et al. Homodimeric structure and double-stranded RNA cleavage activity of the C-terminal RNase III domain of human dicer. J Mol Biol 2007; 374: 106-120.
35. Macrae IJ, Li F, Zhou K, et al. Structure of Dicer and mechanistic implications for RNAi. Cold Spring Harb Symp Quant Biol 2006; 71: 73-80.
36. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 2012; 366: 234-242.
37. Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 2009; 325: 965.
38. Don RH, Cox PT, Wainwright BJ, et al. 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 1991; 19: 4008.
39. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
40. Ng PC, Henikoff S,. Predicting deleterious amino acid substitutions. Genome Res 2001; 11: 863-874.
41. Lastella P, Resta N, Miccolis I, et al. Site directed mutagenesis of hMLH1 exonic splicing enhancers does not correlate with splicing disruption. J Med Genet 2004; 41: e72.
42. Gurtan AM, Lu V, Bhutkar A, et al. In vivo structure-function analysis of human Dicer reveals directional processing of precursor miRNAs. RNA 2012; 18: 1116-1122.
43. Amrein L, Shawi M, Grenier J, et al. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. Int J Cancer 2013; [Epub ahead of print].
44. Wang Z, Rolish ME, Yeo G, et al. Systematic identification and analysis of exonic splicing silencers. Cell 2004; 119: 831-845.
45. Raponi M, Kralovicova J, Copson E, et al. Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6. Hum Mutat 2011; 32: 436-444.
46. Rio Frio T, Bahubeshi A, Kanellopoulou C, et al. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. J Am Med Assoc 2011; 305: 68-77.
47. Sterne-Weiler T, Howard J, Mort M, et al. Loss of exon identity is a common mechanism of human inherited disease. Genome Res 2011; 21: 1563-1571.
48. Bonnet C, Krieger S, Vezain M, et al. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 2008; 45: 438-446.
49. Harfe BD, McManus MT, Mansfield JH, et al. The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. Proc Natl Acad Sci USA 2005; 102: 10898-10903.
50. Anglesio M, Wang Y, Yang W, et al,. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J Pathol 2013; 229: 400-409.
51. Zin R, Pham K, Ashleigh M, et al. SNP-based arrays complement classic cytogenetics in the detection of chromosomal aberrations in Wilms' tumor. Cancer Genet 2012; 205: 80-93.
52. Morrison AA, Viney RL, Ladomery MR,. The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta 2008; 1785: 55-62.
53. de Boer CM, Eini R, Gillis AM, et al. DICER1 RNase IIIb domain mutations are infrequent in testicular germ cell tumours. BMC Res Notes 2012; 5: 2101791285670510.
54. Vandin F, Upfal E, Raphael BJ,. Finding driver pathways in cancer: models and algorithms. Algorithms Mol Biol 2012; 7: 23.
55. Kort EJ, Farber L, Tretiakova M, et al. The E2F3-Oncomir-1 axis is activated in Wilms' tumor. Cancer Res 2008; 68: 4034-4038.
56. Li JY, Yong TY, Michael MZ, et al. Review: the role of microRNAs in kidney disease. Nephrology (Carlton) 2010; 15: 599-608.
57. Senanayake U, Das S, Vesely P, et al. miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 2012; 33: 1014-1021.
58. Nagalakshmi VK, Ren Q, Pugh MM, et al. Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int 2011; 79: 317-330.
59. Bartram MP, Hohne M, Dafinger C, et al,. Conditional loss of kidney microRNAs results in congenital anomalies of the kidney and urinary tract (CAKUT). J Mol Med (BerlNN 2013; in press.